The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
about
The Simcyp population-based ADME simulatorA phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancerErlotinib and pantoprazole: a relevant interaction or not?Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.Drug-drug interaction pattern recognition.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Safety of triazole antifungal drugs in patients with cancer.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domainCYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.Aprepitant for the Treatment of Chronic Refractory Pruritus.Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method.Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced PractitionerImpact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats
P2860
Q28308225-264D6208-D943-48C9-8614-DF1B06E9DC53Q34132656-0ADB4BCD-43B8-47EE-B71E-C1FFDEDE6646Q34266864-022571BE-B5DD-4362-AF16-995A26517681Q34398312-EF697C49-4FD6-43FB-A388-62BD5F5FAC3FQ34457467-BB2B75D6-CFDE-4733-B849-A739A61B2FA7Q34476096-13613C33-F77C-473B-964D-7B999BFD80F1Q35015993-491C7F2E-467A-435C-BBE4-EA52E0F569CDQ35667342-17CF1CFF-AF1E-4BF0-9AE1-D385E503696CQ36040272-F91C7A60-3261-4DFA-B158-9FBAE93A3CE1Q36080621-0DCD3308-8E0C-4B7B-9238-A509B9385458Q36649880-865CBE67-8FE4-4590-BE06-AB426FC96E0EQ36713494-E3038FFC-5E6E-42FA-AC1F-2029BEB3F286Q37193103-0BB50E92-516A-4AE2-A465-5B455E22F342Q37662650-BD1573E2-51B4-4A6D-994C-87A8375D14D6Q37873453-4B3E36B8-0DAB-450A-944A-F8AAFC93D272Q37898325-E92A13C9-602C-464A-8418-2D75F320A2B0Q37960638-58C58FAE-6828-433E-A45A-FC8552B68FC6Q37981002-A53B1CCC-B61A-458C-B585-D82EBE66E7ADQ38099040-DC4A12BE-12A2-4FD1-8203-9906B56F5587Q39031326-07E1A371-5B78-4D87-9AEE-F9B8BF7BF870Q39321056-948E43DA-75E3-442D-B6D1-424D4CD641CCQ39732707-66EA7B1C-BBE5-4ECC-B56C-0FD0F5CA9C24Q41983319-14F679FD-9059-4A48-B22F-9104935E7412Q44784776-165F029B-58B4-4135-A5FA-4CBBD9434A84Q45939780-3F068F14-84D0-4265-B612-BA304E5F9BF7Q47141491-03A26139-B889-4545-BFDB-E7756D746D0AQ47885966-5C5858EC-F009-4DF1-948E-D43BD4134CEEQ49449657-81CC04CE-E978-4BA4-BA61-BAACD090AAF2Q54178349-BCA057E2-A145-4A73-9747-1F42D26B4FE4Q54316808-1D98F9BB-6829-4071-9B4C-FA18A96F720CQ54381356-EF1444F7-47E1-4CDB-BC45-945F0868061DQ57498748-885E1F34-96F6-467B-A2CB-9CDF28C0C214Q58774388-2B8519D5-DB3F-4A24-8A55-F17CAC9E3464
P2860
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The effects of CYP3A4 inhibiti ...... in vivo metabolic inhibition.
@en
type
label
The effects of CYP3A4 inhibiti ...... in vivo metabolic inhibition.
@en
prefLabel
The effects of CYP3A4 inhibiti ...... in vivo metabolic inhibition.
@en
P2093
P1476
The effects of CYP3A4 inhibiti ...... in vivo metabolic inhibition.
@en
P2093
Ashok Rakhit
Bert L Lum
Hannah M Jones
Jean-Eric Charoin
Marta Hamilton
Michael P Pantze
Myriam Riek
Scott Fettner
P2888
P356
10.1007/S00228-007-0396-Z
P577
2007-11-14T00:00:00Z